Second drug attempts to rescue weaker CAR-T results in blood cancer
NCT ID NCT06523621
Summary
This study is testing whether adding the immunotherapy drug nivolumab can improve treatment outcomes for patients with hard-to-treat multiple myeloma. The trial focuses on 50 patients whose cancer did not respond well enough to a specialized CAR-T cell therapy called idecabtagene vicleucel. Researchers will give nivolumab to see if it helps the CAR-T cells work better and leads to deeper cancer remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27103, United States
Contact
Contact Email: •••••@•••••
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.